Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prophylactic anticoagulants for people hospitalized with COVID-19: systematic review.

The British journal of surgery·2021

Same author

Minoxidil for patchy alopecia areata: systematic review and meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

Same author

Aspirin plus calcium supplementation to prevent superimposed preeclampsia: a randomized trial.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2014

Same author

Treatment for agenesis of maxillary lateral incisors: a systematic review.

Orthodontics & craniofacial research·2013

Same author

Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2008

Same author

Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy.

The Cochrane database of systematic reviews·2008

Search research articles

Related Experiment Videos

Pentoxifylline for diabetic retinopathy.

C C Lopes de Jesus¹, A N Atallah, O Valente

¹Brazilian Cochrane Center, Escola Paulista de Medicina (EPM) - Universidade Federal de São Paulo (UNIFESP), Rua Pedro de Toledo, 598, São Paulo, Brazil, 04039-001. caceloje@gmail.com

The Cochrane Database of Systematic Reviews

|April 22, 2008

Summary

No studies met the criteria to evaluate pentoxifylline for diabetic retinopathy. Further research is needed to determine if this drug impacts the progression of diabetic retinopathy or blindness.

Related Experiment Videos

Area of Science:

Ophthalmology
Pharmacology
Diabetology

Background:

Diabetic retinopathy is linked to capillary occlusion.
Pentoxifylline, a disaggregant, may affect diabetic retinopathy outcomes.
No systematic review exists on pentoxifylline's efficacy and safety for diabetic retinopathy.

Purpose of the Study:

To systematically review literature on pentoxifylline for diabetic retinopathy.
To assess pentoxifylline's effects in methodologically robust trials.
To test the hypothesis that pentoxifylline does not influence diabetic retinopathy progression or blindness.

Main Methods:

Systematic search of electronic databases for relevant publications.
Inclusion of only randomized controlled clinical trials (RCTs).
Independent assessment of studies for inclusion criteria and risk of bias by two authors.

Main Results:

97 publications were identified; 17 were potentially relevant.
Full texts of 17 trials were reviewed.
No publications met the inclusion criteria for the systematic review.

Conclusions:

No robust research currently supports pentoxifylline for diabetic retinopathy treatment.
The efficacy of pentoxifylline in diabetic retinopathy remains undetermined.
Future research should focus on patient-relevant outcomes to address this issue.